

NIH Public Access Author Manuscript

Cell Author manuscript: available in PMC 2010 Octo

Published in final edited form as: *Cell*. 2009 July 10; 138(1): 210–210.e1. doi:10.1016/j.cell.2009.06.026.

SnapShot: Ca²⁺-Calcineurin-NFAT Signaling

Gerald R. Crabtree¹ and Stuart L. Schreiber²

¹ Stanford University School of Medicine, Stanford, CA 94305, USA

² Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA

Ca²⁺-calcineurin-NFAT signaling transmits signals to the nucleus from a wide variety of receptors and is required for developmental events as diverse as axon outgrowth, cardiac morphogenesis, lung morphogenesis, neural crest diversification, epithelial stem cell maintenance, and immune responses. The pathway appears to be particularly dedicated to vertebrate-specific morphogenic events, perhaps reflecting its first evolutionary appearance in vertebrates. Calcineurin-NFAT signaling is the target of the drugs cyclosporin A and FK506 and several viral immune modulators. In addition, its malfunction is implicated in Down's syndrome, diabetes, and cardiac hypertrophy.

Receptors that induce the entry of Ca^{2+} into the cell resulting in the activation of calcineurin phosphatase are shown in the lower left. Ca²⁺ binds to the regulatory subunit of calcineurin as well as to calmodulin to activate the phosphatase activity of calcineurin (Stemmer and Klee, 1994). The immunosuppressive drugs FK506 and cyclosporin A inhibit calcineurin by binding first to the abundant intracellular proteins, FKBP and cyclophilin, respectively. These protein complexes then bind to calcineurin, preventing substrate access (Liu et al., 1991). The specificity of these calcineurin inhibitors is due to the large composite surface arising from FKBP bound to FK506 (see inset structure) (Griffith et al., 1995) or cyclosporin A bound to cyclophilin. FK506 and cyclosporin A are highly specific probes of the NFAT signaling pathway in tissues where the concentration of calcineurin is less than the concentration of FKBP or cyclophilin (Graef et al., 2001). Calcineurin removes several phosphate residues from the N terminus of NFATc proteins, the Ca²⁺-calcineurin-sensitive subunits of NFAT transcription complexes. Removal of the phosphates exposes nuclear localization sequences in NFATc proteins leading to their rapid entry into the nucleus (Beals et al., 1997a). Once in the nucleus, the NFATc proteins assemble on DNA with partner proteins generically termed NFATn (lower right) that are often the endpoints of other signaling pathways (Crabtree and Olson, 2002). In most cases, NFAT-dependent transcription requires that the Ca^{2+} signaling be coincident with MAP kinase signaling, providing a mechanism for signal integration and coincidence detection.

The targets of NFAT signaling (panel, upper right) are largely cytokines, growth factors and their receptors, proteins involved in cell-cell interactions, as well as many microRNAs. Of particular importance are positive feedback loops initiated by direct binding of NFATc1 and NFATc4 to their promoters as well as the regulation of Ca^{2+} channels, such as the IP3 receptor, responsible for the release of intracellular Ca^{2+} stores (Genazzani et al., 1999). This positive feedback loop appears to be important in committing cells to specific fates. A negative feedback loop mediated by the NFAT-dependent activation of *RCAN* (*DSCR1*) gene expression appears to constrain the pathway (Arron et al., 2006).

NFATc proteins are actively removed from the nucleus by first priming with Dyrk1a or protein kinase A (PKA) followed by phosphorylation by GSK3 (Arron et al., 2006; Beals et al., 1997b; Gwack et al., 2006). The inhibition of GSK3 by AKT and PI3 kinase (PI3K) signaling increases the level of NFATc proteins in the nucleus and hence provides a second means of coincidence detection and signal integration. Many of the phenotypes of Down's syndrome

are thought to be due to the duplication of the *DSCR* and *Dyrk1a* genes on chromosome 21. Increased gene dosage both reduces NFATc import into the nucleus and also facilitates export leading to a reduction in NFATc function and compromised positive feedback (Arron et al., 2006).

Abbreviations


| AKT | the cellular homolog of the acute transforming oncogene v-AKT |
|------------|--|
| BCR | B cell receptor |
| CRAC | Ca ²⁺ release-activated Ca ²⁺ channel |
| DSCR1/RCAN | Down's syndrome critical region 1, now called regulator of calcineurin |
| Dyrk1a | dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A |
| FKBP | FK506-binding protein |
| GSK3 | glycogen synthease kinase 3 |
| IP3R1 | inositol 1,4,5-triphosphate receptor 1 |
| NFAT | nuclear factor of activated T cells |
| NMDA | N-methyl-D-aspartate receptor |
| NFATc | Ca ²⁺ -calcineurin-dependent subunits of NFAT complexes, also cyclosporin-sensitive subunit of NFAT complexes |
| NFATn | generic name for nuclear subunits of NFAT-transcription complexes |
| NF-кB | nuclear factor binding to the immunoglobulin kappa locus in B cells |
| РІЗК | phosphatidylinositol 3-kinase |
| IP3 | inositol 1,4,5-triphosphate |
| PLCγ | phospholipase gamma |
| STIM | stromal interaction molecule |
| Sox2 | sex determination-box containing gene |
| TRP | transient receptor potential channel |
| TCR | T cell receptor |
| VEGF | vascular endothelial growth factor |
| | |

References

- Arron JR, Winslow MM, Polleri A, Chang CP, Wu H, Gao X, Neilson JR, Chen L, Heit JJ, Kim SK, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006;441:595–600. [PubMed: 16554754]
- Beals CR, Clipstone NA, Ho SN, Crabtree GR. Nuclear localization of NF-ATc by a calcineurindependent, cyclosporin- sensitive Intramolecular interaction. Genes Dev 1997a;11:824–834. [PubMed: 9106655]
- Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997b;275:1930–1934. [PubMed: 9072970]
- Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 2002;109 (Suppl):S67–S79. [PubMed: 11983154]
- Genazzani AA, Carafoli E, Guerini D. Calcineurin controls inositol 1,4,5-trisphosphate type 1 receptor expression in neurons. Proc Natl Acad Sci USA 1999;96:5797–5801. [PubMed: 10318964]

- Graef IA, Chen F, Chen L, Kuo A, Crabtree GR. Signals transduced by Ca(2+)/calcineurin and NFATc3/ c4 pattern the developing vasculature. Cell 2001;105:863–875. [PubMed: 11439183]
- Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon MJ, Fleming MA, Caron PR, Hsiao K, Navia MA. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12–FK506 complex. Cell 1995;82:507–522. [PubMed: 7543369]
- Gwack Y, Sharma S, Nardone J, Tanasa B, Iuga A, Srikanth S, Okamura H, Bolton D, Feske S, Hogan PG, et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 2006;441:646–650. [PubMed: 16511445]
- Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807–815. [PubMed: 1715244]
- Stemmer PM, Klee CB. Dual calcium ion regulation of calcineurin by calmodulin and calcineurin B. Biochemistry 1994;33:6859–6866. [PubMed: 8204620]

Crabtree and Schreiber



1. .

Cell. Author manuscript; available in PMC 2010 October 20.